ReviewExperimental hematology2008
Autologous umbilical cord blood infusion for type 1 diabetes.
Review in Experimental hematology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00873925 (Transfusion of Autologous Umbilical Cord Blood Plus Vitamin D and Omega 3 Fatty Acids to Preserve Beta Cell Function in Children With Recent Onset Type 1 Diabetes - A Pilot Study), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transfusion of Autologous Umbilical Cord Blood Plus Vitamin D and Omega 3 Fatty Acids to Preserve Beta Cell Function in Children With Recent Onset Type 1 Diabetes - A Pilot Study
Who cites it
34 citing papers in PubMed, 132 citations in OpenAlex.
- Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: preliminary results.Medical science monitor : international medical journal of experimental and clinical research · 2013Trial
- Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Trial
- Umbilical cord blood derived cell expansion: a potential neuroprotective therapy.Stem cell research & therapy · 2024Review
- An optimized method for obtaining clinical-grade specific cell subpopulations from human umbilical cord-derived mesenchymal stem cells.Cell proliferation · 2022Article
- Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.Journal of translational medicine · 2021Review
- Review
- Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application.Stem cell research & therapy · 2020Review
- The effect of human wharton's jelly-derived mesenchymal stem cells on MC4R, NPY, and LEPR gene expression levels in rats with streptozotocin-induced diabetes.Iranian journal of basic medical sciences · 2020Article
- Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model.Stem cell research & therapy · 2019Article
- An Artificial Tissue Homeostasis Circuit Designed via Analog Circuit Techniques.IEEE transactions on biomedical circuits and systems · 2019Article
- Review
- Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.Molecular therapy. Methods & clinical development · 2017Article
- Implantation of placenta-derived mesenchymal stem cells accelerates murine dermal wound closure through immunomodulation.American journal of translational research · 2016Article
- HUCBCs increase angiopoietin 1 and induce neurorestorative effects after stroke in T1DM rats.CNS neuroscience & therapeutics · 2014Article
- Autografting of bone marrow mesenchymal stem cells alleviates streptozotocin‑induced diabetes in miniature pigs: real-time tracing with MRI in vivo.International journal of molecular medicine · 2014Article
- Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide.Diabetes care · 2011Article
- Umbilical cord blood: current status & promise for the future.The Indian journal of medical research · 2011Review
- Use of a precious resource: parental decision making about using autologous umbilical cord blood in studies involving young children with type 1 diabetes.Contemporary clinical trials · 2011Article
- The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine.Cell proliferation · 2011Review
- Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.International journal of clinical and experimental medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe physical, emotional, and economic costs of type 1 diabetes (T1D) mandate continued efforts to develop effective strategies to prevent or reverse the disease. Herein, we describe the scientific and therapeutic rationale underlying efforts utilizing umbilical cord blood (UCB) as a therapy for ameliorating the progression of this autoimmune disease. MATERIALS AND
methodsWe recently embarked on a pilot study to document the safety and potential efficacy of autologous UCB infusion in subjects with T1D. Under this protocol, patients recently diagnosed with the disease and for whom autologous cord blood is stored, undergo infusion. Studies are performed before infusion and every 3 to 6 months postinfusion for immunologic and metabolic assessment. To date, 15 autologous infusions have been performed.
resultsPreliminary observations suggest that autologous cord blood transfusion is safe and provides some slowing of the loss of endogenous insulin production in children with T1D. Mechanistic studies demonstrate that umbilical cord blood contains highly functional populations of regulatory T cells (Treg) and that increased Treg populations may be found in the peripheral blood of subjects more than 6 months after cord blood infusion. We provide the rationale for cord blood-based therapies, a summary of our initial protocol, and plans for future studies designed to explore the potential of cord blood-derived regulatory T cells to treat T1D.
conclusionsProlonged follow-up and additional mechanistic efforts are urgently needed to determine if umbilical cord blood-derived stem cells can be used as part of safe and effective therapies for T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.